Back Treatment of patients with ACEi or ARB in relation to COVID-19
The British Cardiovascular Society (BCS) together with the British Society for Heart Failure (BSH) have released the following joint statement with regards to the treatment of patients with ACEi or ARB in relation to COVID-19 as a response to press and social media coverage raising 'the possibility that treatment with ACEi or ARB could predispose individuals to adverse outcomes should they become infected with COVID-19,
'there is no evidence to support this assertion and that both organisations share the view of the European Society of Hypertension and the Renal Association that patients should continue treatment with ACEi and ARB unless specifically advised to stop by their medical team.'
Both Societies recommend that patients taking these drugs and presenting unwell with suspected or known COVID-19 infection should be assessed on an individual basis and their medication managed according to established guidance as found.
The Primary Care Cardiovascular Society fully supports the views expressed in the Joint British societies statement and those of the European Society of Hypertension and the Renal Association.
In line with these statements, PCCS have developed some specific advice for patients which can be found here COVID_19_and_cardiac_treatment.pdf